<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532178</url>
  </required_header>
  <id_info>
    <org_study_id>MISP#56343</org_study_id>
    <nct_id>NCT03532178</nct_id>
  </id_info>
  <brief_title>Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)</brief_title>
  <acronym>CRoSSECT</acronym>
  <official_title>A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to compare the recovery of neuromuscular blockade from rocuronium
      reversal by sugammadex to succinylcholine in ECT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a single center, randomized, double-blind (patients, psychiatrists and
      outcome assessor), cross-over clinical trial comparing the recovery of neuromuscular blockade
      from rocuronium with reversal of sugammadex to succinylcholine in participants receiving ECT.
      The primary outcome will be the measurement of time when the first train-of-four (TOF) twitch
      (T1) returns to 90% of baseline. The secondary aims are to document the safety (adverse event
      rates) of rocuronium/sugammadex compared to succinylcholine in ECT patients. The exploratory
      aims are to establish the perioperative efficacy and efficiency of sugammadex reversal of
      rocuronium in ECT procedures in comparison with succinylcholine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The participants will be randomized to one of the two drug groups to start with, and will switch to the other group for the next treatment period. For the study, each participant will take two treatments in a random order: (1) rocuronium to be reversed by sugammadex, and (2) succinylcholine plus normal saline placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization of treatment groups will be blinded to the patients themselves, the psychiatrists and outcome assessors, except the anesthesiologists who will administer the drugs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery time of T1 to 90% baseline</measure>
    <time_frame>30 minutes</time_frame>
    <description>The time of neuromuscular recovery from sugammadex 4mg/kg dose reversal rocuronium at 0.6 mg/kg compared with traditionally used succinylcholine in electroconvulsive therapy (ECT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment or emergent adverse events of the drugs</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>To document the side-effect profiles of sugammadex reversal of rocuronium and succhinylcholine in the ECT patient population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rocuronium + sugammadex / succinylcholine + normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>succinylcholine + normal saline / rocuronium + sugammadex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A. &quot;Muscle relaxant #1&quot;: rocuronium + sugammadex; &quot;Muscle relaxant #2&quot;: succinylcholine +saline</intervention_name>
    <description>The participants will be randomized to start with &quot;Muscle relaxant #1&quot; in the first study treatment, and will switch to &quot;Muscle relaxant #2&quot; in the second study treatment period.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Rocuronium: Zemuron. Sugammadex: Bridion. Succinylcholine: Suxamethonium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B. &quot;Muscle relaxant #2&quot;: succinylcholine +saline; &quot;Muscle relaxant #1&quot;: rocuronium + sugammadex;</intervention_name>
    <description>The participants will be randomized to start with &quot;Muscle relaxant #2&quot; in the first study treatment, and will switch to &quot;Muscle relaxant #1&quot; in the second study treatment period.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible and scheduled for ECT

          -  Has the capacity to consent for the study

        Exclusion Criteria:

          -  Any acute major organ failure in the last 30 days

          -  Any known or suspected neuromuscular disorders

          -  Any history of allergic reaction or intolerance to sugammadex, rocuronium, or
             succinylcholine

          -  Any conditions with severe renal impairment, including those requiring dialysis

          -  Anyone currently taking lithium

          -  Anyone currently taking hormonal contraceptives

          -  Anyone taking anti-coagulants, including vitamin K antagonists, unfractionated
             heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chanhung Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chanhung Lee, MD, PHD</last_name>
    <phone>415-206-8906</phone>
    <email>Chanhung.lee@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Parnassus Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chanhung Lee, MD, PhD</last_name>
      <phone>415-206-8906</phone>
      <email>Chanhung.lee@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007 Nov 8;357(19):1939-45. Review.</citation>
    <PMID>17989386</PMID>
  </results_reference>
  <results_reference>
    <citation>Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997-2011. Acta Psychiatr Scand. 2014 Jun;129(6):417-26. doi: 10.1111/acps.12251. Epub 2014 Feb 12. Review.</citation>
    <PMID>24571807</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman S, Baker T, Gatti M, Simon G, Paskin S. Probable succinylcholine-induced rhabdomyolysis in a male athlete. Anesth Analg. 1995 Aug;81(2):422-3.</citation>
    <PMID>7618742</PMID>
  </results_reference>
  <results_reference>
    <citation>Iwatsuki N, Kuroda N, Amaha K, Iwatsuki K. Succinylcholine-induced hyperkalemia in patients with ruptured cerebral aneurysms. Anesthesiology. 1980 Jul;53(1):64-7.</citation>
    <PMID>7386911</PMID>
  </results_reference>
  <results_reference>
    <citation>Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005 Oct;103(4):695-703.</citation>
    <PMID>16192761</PMID>
  </results_reference>
  <results_reference>
    <citation>Ali HH, Utting JE, Nightingale DA, Gray C. Quantitative assessment of residual curarization in humans. Br J Anaesth. 1970 Sep;42(9):802-3.</citation>
    <PMID>4248487</PMID>
  </results_reference>
  <results_reference>
    <citation>Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4. Review.</citation>
    <PMID>20442260</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009 May;110(5):1020-5. doi: 10.1097/ALN.0b013e31819dabb0.</citation>
    <PMID>19387176</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirzakhani H, Guchelaar HJ, Welch CA, Cusin C, Doran ME, MacDonald TO, Bittner EA, Eikermann M, Nozari A. Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial. Anesth Analg. 2016 Sep;123(3):587-96. doi: 10.1213/ANE.0000000000001218.</citation>
    <PMID>26967896</PMID>
  </results_reference>
  <results_reference>
    <citation>Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007 May;106(5):935-43.</citation>
    <PMID>17457124</PMID>
  </results_reference>
  <results_reference>
    <citation>Kadoi Y, Hoshi H, Nishida A, Saito S. Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy. J Anesth. 2011 Dec;25(6):855-9. doi: 10.1007/s00540-011-1236-y. Epub 2011 Sep 24.</citation>
    <PMID>21947754</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroconvulsive Therapy, Neuromuscular Blockade</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

